All News

Olaparib, a PARP inhibitor approved for treating BRCA1/2-mutated ovarian cancer, has been found effective in treating men with metastatic, castrate-resistant prostate cancer.

The study found subtypes aligned by likelihood to be obese, to have cancer or heart disease, or to have mental illness.

What we're reading, October 29, 2015: Pfizer and Allergan in talks to merge; the House passes a budget deal with implications for Medicare beneficiaries; and autism in children is being overdiagnosed.

The drug significantly delayed recurrence of the cancer in patients treated post surgery.

What we're reading, October 28, 2015: Ben Carson plans to replace the Affordable Care Act, Medicaid, and Medicare; a homeless shelter utilizes telemedicine to alleviate emergency department visits; and researchers uncover gender gap in post-heart attack treatment.

A forum presented by Horizon Blue Cross Blue Shield of New Jersey and The Atlantic casts the debate over a state-level population health plan against national healthcare cost trends.

Twenty-four states have received grants to improve the behavioral health of their citizens by providing community-based mental and substance use disorder treatment.

Experiments with rats showed that specially engineered polymer patches attached to the intestine and delivered insulin.

Consolidation in the healthcare market continues with an announcement that Walgreens has entered into an agreement to purchase Rite Aid for a total of $17.2 billion.

The company says the treatment will cost an average of $65,000.

The ASCO statement emphasizes patient-centered reform that weighs-in the value of the services rendered.

Study finds a "lost opportunity" to reduce overtreatment and potential medication harm among patients with diabetes.

The ADA's Safe at School campaign seeks to highlight the need for personnel other than nurses to learn to help students with type 1 diabetes with insulin and glucagon. The population of students with type 1 is increasing.

While the age-standardized death rate for all causes of death combined, as well as heart disease, cancer, stroke, unintentional injuries, and diabetes, have slowed from 1969 to 2013, the rate for chronic obstructive pulmonary disease actually increased.

What we're reading, October 27, 2015: a much-improved Healthcare.gov website, report says drug prices rose at a much slower rate in 2015, and USPSTF recommends glucose testing in asymptomatic adults who are overweight or obese.

A study shows too much conflicting dietary advice causes some people to tune it all out. Nuances in the report from WHO are lost on most consumers.

The vaccine, approved in Europe last week, is now awaiting approval in the United States.

Despite the fact that post-bronchodilator spirometry is required for the diagnosis of chronic obstructive pulmonary disease, an analysis of primary care clinics found only 19% of patients diagnosed with the disease had undergone spirometry testing.

Women who had risk factors for weight gain but were not overweight when they got pregnant were most likely to retain weight if they gained too much during pregnancy.

Some consumer-friendly features are still in final testing.

Three important patient-reported outcomes can help predict hospitalizations among patients with chronic obstructive pulmonary disease, potentially helping clinicians to categorize patients' level of risk and design preventive interventions and proper care.

In this AJMC Industry Outlook webinar "The Role of Real-World Evidence in Successful Product Commercialization," we discuss a framework to identify and validate the need for external customer-facing evidence generation and review how the framework can be applied. By the end of this discussion, you will have a deeper understanding of how to frame and justify investment in health economics and outcomes research, and real-world evidence generation.

What we're reading, October 26, 2015: One-third of uninsured in California are unaware of premium subsidies and medical school enrollment among black men is down.

A study published in the journal Cancer presents the financial impact of cancer on a survivor and his family.

A new health insurance start-up aiming to aid companies with their employer-sponsored insurance raised $81 million in a new round of financing. The new funding will allow the company to expand its services beyond California in 2016.

Two head-to-head trials comparing the safety of Incruse Ellipta to 2 available bronchodilator treatments used by patients with chronic obstructive pulmonary disease has yielded positive results for GlaxoSmithKline's therapy.

This week in managed care, documents show Horizon Blue Cross Blue Shield of NJ rolled out OMNIA prior to receiving regulatory approval, 2 Harvard professors argue the merit of the annual physical, and experts weigh in on the successes and flaws of Medicare Part D.

CMS has unveiled the latest improvements to HealthCare.gov. However, the agency was not able to complete all additional features in time for open enrollment and will roll the remaining ones out after November 1.

Years after the country was sent into a tizzy over the fear of "death panels," there has been an enormous growth in palliative care in the United States, although it and hospice care are still very misunderstood by patients, said speakers at America's Health Insurance Plans' National Conference on Medicaid.

The drug is awaiting an FDA verdict next week.